In this secondary analysis of the ECOG-ACRIN E2906 study, researchers assessed vulnerabilities of AML patients aged 60 years or older and their affect on survival outcomes.
Efficacy and safety of rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting in subjects receiving highly emetogenic chemotherapy. Development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback